Development Strategy - Yantai Dongcheng Pharmaceutical Group Co., Ltd.

About Us / ABOUT US

About Us




We place equal emphasis on both API and preparation businesses, endogenous growth and extensive expansion; continuously consolidate the foundation of characteristic APIs, vigorously develop the preparation business, further improve the product line deployment in the field of anticoagulation, and become a leader in the niche therapeutic areas.

With the nuclide drugs as the new core competitiveness of the company, we will perfect the domestic nuclide drug network, and build up a platform for the entire value industry chain of the nuclide drug under the development ideas of “wading into the upstream, integrating the downstream and deploying the frontier”.

We will increase investment in R&D, enhance the strength in this aspect, focus on the development of innovative medicines for malignant tumors, neurodegenerative diseases and cardiovascular and cerebrovascular diseases, and introduce and develop the latest diagnostic and therapeutic nuclide drugs to fill in the gaps in China for the benefit of patients.


Add:No.7 ChangBaiShan Road, Yantai Development Zone, ShanDong, China
About Us
Company Profile
Chairman Address
Honors of Dongcheng
Evolutional History
Development Strategy
Corporate Culture
Contact Us
Group News
Media Coverage
API Series
Preparation Series
Nuclide Drug Series
Health Care Business
Technology Platform
Honors and Qualifications
Advanced Equipment
Talent Concepts
Talent Development
Talent Recruitment
Instant Quotes
Regular Reports
Investor Services
Social Welfare
Safety & Environmental Protection
Occupational Health
COPYRIGHT 2020 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All rights reserved 鲁ICP备13809311号-1